Cargando…

Efficacy and tolerance of LV5FU2-carboplatin chemotherapy in patients with advanced pancreatic ductal adenocarcinoma after failure of standard regimens

BACKGROUND: Chemotherapy options in patients with advanced pancreatic ductal adenocarcinoma (PDAC) after failure of standard chemotherapies are limited. OBJECTIVES: We aimed to report the efficacy and safety of the leucovorin and 5-fluorouracil (LV5FU2) and carboplatin combination in this setting. D...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chaigneau, Thomas, Aguilera Munoz, Lina, Oger, Caroline, Gourdeau, Clémence, Hentic, Olivia, Laurent, Lucie, Muller, Nelly, Dioguardi Burgio, Marco, Gagaille, Marie-Pauline, Lévy, Philippe, Rebours, Vinciane, Hammel, Pascal, de Mestier, Louis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052496/ https://www.ncbi.nlm.nih.gov/pubmed/37007630 http://dx.doi.org/10.1177/17588359231163776

Ejemplares similares

FOLFOX‐bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors
por: Lacombe, Caroline, et al.
Publicado: (2023)

Fatal Bile Duct Necrosis: A Rare Complication of Transcatheter Arterial Chemoembolization in a Patient with Endocrine Hepatic Metastasis
por: Pelletier, Anne-Laure, et al.
Publicado: (2008)

Prolonged Survival in a Patient with Neuroendocrine Tumor of the Cecum and Diffuse Peritoneal Carcinomatosis
por: de Mestier, Louis, et al.
Publicado: (2012)

nal‐IRI+5‐FU/LV versus 5‐FU/LV in post‐gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients
por: Ueno, Makoto, et al.
Publicado: (2020)

Role of endoscopic ultrasound in the screening and follow-up of high-risk individuals for familial pancreatic cancer
por: Lorenzo, Diane, et al.
Publicado: (2019)

Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis
por: Pelzer, Uwe, et al.
Publicado: (2017)

CT-Based Radiomics Analysis to Predict Malignancy in Patients with Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas
por: Tobaly, David, et al.
Publicado: (2020)

A Highly Active and Tolerable Neoadjuvant Regimen Combining Paclitaxel, Carboplatin, 5-FU, and Radiation Therapy in Patients with Stage II and III Esophageal Cancer
por: van de Schoot, L., et al.
Publicado: (2007)

Natural history of SPINK1 germline mutation related-pancreatitis
por: Muller, Nelly, et al.
Publicado: (2019)

A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial
por: Bachet, Jean-Baptiste, et al.
Publicado: (2015)

Differential Diagnosis of Cystic Pancreatic Lesions Including the Usefulness of Biomarkers
por: Lévy, Philippe, et al.
Publicado: (2015)

A case of pathological complete response with liposomal irinotecan + 5-FU/LV for unresectable locally advanced pancreatic cancer
por: Kikuchi, Koji, et al.
Publicado: (2022)

Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial
por: Skof, Erik, et al.
Publicado: (2009)

Pharmacokinetics of preoperative intraperitoneal 5-FU in patients with pancreatic ductal adenocarcinoma
por: Öman, Mikael, et al.
Publicado: (2021)

Pancreatic Ductal Adenocarcinoma Arising in Young and Old Patients Displays Similar Molecular Features
por: Raffenne, Jérôme, et al.
Publicado: (2021)

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial
por: Cassidy, J, et al.
Publicado: (2006)

A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases
por: Bathe, Oliver F, et al.
Publicado: (2009)

Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis
por: Chen, Ke, et al.
Publicado: (2016)

Cisplatin/5-Fluorouracil (5-FU) Versus Carboplatin/Paclitaxel Chemoradiotherapy as Definitive or Pre-Operative Treatment of Esophageal Cancer
por: Steber, Cole, et al.
Publicado: (2021)

Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)
por: Dahan, Laetitia, et al.
Publicado: (2010)

Spatial and temporal heterogeneity of digestive neuroendocrine neoplasms
por: Bourdeleau, Pauline, et al.
Publicado: (2023)

In vitro, in vivo and ex vivo demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma
por: Dayot, Stéphanie, et al.
Publicado: (2018)

A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients
por: Mabro, M, et al.
Publicado: (2006)

Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial
por: Macarulla Mercadé, Teresa, et al.
Publicado: (2020)

Simultaneous quantification method for 5-FU, uracil, and tegafur using UPLC-MS/MS and clinical application in monitoring UFT/LV combination therapy after hepatectomy
por: Shiraiwa, Ken, et al.
Publicado: (2021)

'JEB'--a carboplatin based regimen for malignant germ cell tumours in children.
por: Pinkerton, C. R., et al.
Publicado: (1990)

Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report
por: Sokolova, Alexandra, et al.
Publicado: (2017)

Erratum in Volume LV
Publicado: (1841)

3D Strain helps relating LV function to LV and structure in athletes
por: Stefani, Laura, et al.
Publicado: (2014)

Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin Vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial)
por: Tsakonas, Georgios, et al.
Publicado: (2020)

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
por: Huang, Liang, et al.
Publicado: (2017)

Embolised ASD device in LV
por: Raut, Monish S., et al.
Publicado: (2016)

Dr. Lothrop.—Volume LV
Publicado: (1899)

Gastric Juvenile Polyposis with High-Grade Dysplasia in Pachydermoperiostosis
por: de Mestier, L., et al.
Publicado: (2011)

An Unconventional Regimen of Carboplatin and Paclitaxel in Metastatic Colorectal Carcinosarcoma: A Case Report and Review of Literature
por: Park, Changsu Lawrence, et al.
Publicado: (2023)

5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs
por: Miura, Koh, et al.
Publicado: (2010)

Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels
por: Kim, Stefano, et al.
Publicado: (2013)

A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma
por: Lim, Sung Hee, et al.
Publicado: (2017)

SCT LV3 Card Manual
por: Stastny, J
Publicado: (2004)

Getting the LV lead to the right spot
por: Jackson, K.P., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_80c9lj6f0b3ibfl0gdg48mslnb